Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Benzinga2025.10.15 11:06
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares